Effect of NIR laser therapy by MLS-MiS source against neuropathic pain in rats: in vivo and ex vivo analysis

Abstract

Neuropathic pain is characterized by an uncertain etiology and by a poor response to common therapies. The ineffectiveness and the frequent side effects of the drugs used to counteract neuropathic pain call for the discovery of new therapeutic strategies. Laser therapy proved to be effective for reducing pain sensitivity thus improving the quality of life. However, its application parameters and efficacy in chronic pain must be further analyzed. We investigated the pain relieving and protective effect of Photobiomodulation Therapy in a rat model of compressive mononeuropathy induced by Chronic Constriction Injury of the sciatic nerve (CCI). Laser (MLS-MiS) applications started 7 days after surgery and were performed ten times over a three week period showing a reduction in mechanical hypersensitivity and spontaneous pain that started from the first laser treatment until the end of the experiment. The ex vivo analysis highlighted the protective role of laser through the myelin sheath recovery in the sciatic nerve, inhibition of iNOS expression and enhancement of EAAT-2 levels in the spinal cord. In conclusion, this study supports laser treatment as a future therapeutic strategy in patients suffering from neuropathic pain induced by trauma.

A 57-Year-Old African American Man with Severe COVID-19 Pneumonia Who Responded to Supportive Photobiomodulation Therapy (PBMT): First Use of PBMT in COVID-19

“…In contrast, the anti-inflammatory cytokine interleukin-10, serum monocytes, and lung macrophages were significantly increased following PBMT [ 15 , 17 ]. The molecular basis of MLS laser anti-inflammatory effects has been demonstrated in murine and in vitro models [ 31 – 33 ]. In particular, it has been shown to inhibit inflammasome activation, inhibiting interleukin-1β and interleukin-18, whose downstream signaling induces the production of interleukin-6, interleukin-8, tumor necrosis factor α (TNF-α), and interferon-γ, which are implicated in ARDS caused by COVID-19 infection [ 14 – 18 , 31 – 33 ].…”

Evaluation of Adjunctive Photobiomodulation (PBMT) for COVID-19 Pneumonia via Clinical Status and Pulmonary Severity Indices in a Preliminary Trial

“…31 Investigation of the mechanism of action underlying the antiinflammatory effects of MLS lasers demonstrated an increase in the production of NLRP 10, a potent inhibitor of the inflammasome. 32,33 NLRP 10 inhibits the conversion of pro-IL 1β and pro-IL 18 in IL1β and IL-18 which blocks the production of many other cytokines and inflammation mediators. 32,33 PBMT has been used to treat respiratory disorders such as pneumonia, asthma or COPD in children, adults, and elderly patients.…”

“…32,33 NLRP 10 inhibits the conversion of pro-IL 1β and pro-IL 18 in IL1β and IL-18 which blocks the production of many other cytokines and inflammation mediators. 32,33 PBMT has been used to treat respiratory disorders such as pneumonia, asthma or COPD in children, adults, and elderly patients. [34][35][36][37][38][39] Clinical studies of more than 1000 patients show positive effects of PBMT on pulmonary conditions, including shortened recovery times, decreased need for medications, reduced respiratory symptoms, and improved parameters in radiological, immunological and blood indicators.…”

“… 32 , 33 NLRP 10 inhibits the conversion of pro-IL 1β and pro-IL 18 in IL1β and IL-18 which blocks the production of many other cytokines and inflammation mediators. 32 , 33 …”

The Impact of Proteomic Investigations on the Development and Improvement of Skin Laser Therapy: A Review Article

“…4 The effects of laser therapy on neuropathic pain were analyzed in rats. 22 Orringer et al quantified the molecular changes resulted from micro ablative resurfacing by the erbium: yttrium aluminium garnet (Er:YAG) laser. They found the up-regulation of keratin 16, IL-1B, and IL-8.…”